HHS has appointed eight new members to the U.S. Preventive Services Task Force after more than a year of inactivity, restoring the panel to 16 members with a notably different composition that includes more specialists and fewer primary care physicians. The reconstitution matters for Medicaid managed care because USPSTF recommendations with A or B grades trigger mandatory coverage without cost-sharing under the ACA, affecting benefit design, utilization management, and preventive service demand across health plans. The panel's new makeup and potential shifts in evidence review approaches could influence future preventive care coverage requirements.

CMS has proposed implementing the OBBBA's provider tax changes with significant new details: state-specific thresholds based on taxes in place as of July 2025, a zero-percent threshold for new tax classes, exemptions for non-expansion states and certain facility types, and elimination of the 75/75 workaround pathway. The rule would reduce federal Medicaid spending by $246 billion over ten years—substantially more than originally estimated—forcing states and MCOs to fundamentally rethink Medicaid financing strategies. The proposal also introduces health insurers as a newly permissible tax class, directly affecting managed care plan operations and rate structures.

Analysis of Q2 2026 earnings from six major publicly traded health plans shows Medicaid managed care operations are under financial strain due to higher-than-expected member acuity and uncertainty around state payment rates and policy changes including redeterminations and work requirements. Unlike Medicare Advantage where plans are prioritizing profitability over growth, Medicaid MCOs remain heavily dependent on state rate adequacy amid ongoing eligibility policy shifts. The findings highlight continuing challenges for Medicaid plan financial sustainability as post-pandemic enrollment dynamics stabilize.

Avalere's new explainer video series addresses regulatory changes affecting health plans, with episodes covering Medicare Advantage risk adjustment methodology shifts, the Clover Health Stars lawsuit implications, and heightened federal program integrity enforcement. While focused primarily on Medicare Advantage rather than Medicaid managed care, the compliance and regulatory themes—particularly around fraud, waste, and abuse oversight—have parallel implications for Medicaid MCO operations and state oversight strategies.

CMS's proposed standardized refund methodologies under the Medicare Drug Negotiation Program would calculate manufacturer rebates differently depending on whether drugs have deep existing discounts or not, creating varying financial impacts across competitive drug classes. This matters for Medicaid managed care because the Medicare negotiated prices will serve as benchmarks and could reshape manufacturer pricing strategies and discount structures that MCOs rely on for pharmacy benefits. Plans with formularies weighted toward either high-discount or low-discount competitive classes may face different financial exposure as these Medicare pricing policies take effect.

State prescription drug affordability boards are increasingly tying their price caps to Medicare negotiated prices rather than developing independent methodologies, with Colorado and Maryland leading this approach for products like Enbrel and Ozempic. However, no upper payment limit has actually taken effect yet, some states have dissolved their boards entirely, and aggressive bills in Virginia have faced repeated vetoes. The shift matters for Medicaid MCOs because these state pricing controls would directly affect pharmacy reimbursement rates and formulary strategies if they ultimately go into effect.

Federal rules implementing January 2027 Medicaid work requirements delegate critical operational decisions to states, including how to define medical frailty exemptions and verify compliance. Early implementation in Nebraska and Montana shows dramatic state variation—from 6,800 qualifying diagnosis codes in one state to fewer than 100 conditions in another—creating complex compliance environments for health plans operating across multiple jurisdictions. MCOs will face differential enrollment impacts, varying administrative burdens, and state-specific verification protocols as they prepare systems for the rollout.

CMS's interim final rule on Medicaid work requirements takes effect January 2027, requiring 80 hours monthly of qualifying activities from most non-pregnant working-age adults. The medical frailty exemption is narrower than expected—requiring both a serious condition and impairment in at least one activity of daily living—meaning many chronically ill enrollees may lose coverage. Avalere estimates 7.8 million could become uninsured by 2034, creating urgent operational and care continuity challenges for MCOs serving affected populations.

Federal Medicaid work requirements mandating 80 hours monthly of community engagement for expansion adults aged 19-64 take effect January 2027, with states responsible for defining exemptions, compliance pathways, and verification processes. The rule creates significant operational and financial uncertainty for Medicaid managed care plans, which must prepare enrollment systems and work with state agencies on implementation decisions that will vary substantially by jurisdiction. Stakeholders including MCOs should engage now during the comment period and state planning phase to shape exemption policies, hardship provisions, and compliance demonstration approaches that will directly affect coverage continuity and plan operations.

CMS's June 2026 interim final rule establishes Medicaid community engagement requirements effective January 2027, applying to non-pregnant adults 19-64 in expansion populations across 43 states and DC. The rule includes a stricter-than-expected medical frailty exemption requiring ADL impairment and prohibits states from delegating eligibility verification to MCOs, while CMS projects combined 15% disenrollment from noncompliance and procedural issues. MCOs must now prepare operational strategies to mitigate enrollment loss and support members in meeting requirements, even as they cannot directly perform eligibility verification.

Federal disruption to ACIP has created challenges for Medicaid managed care organizations as they manage immunization coverage policies amid fragmented guidance from multiple clinical bodies. While a March 2026 injunction preserved broad vaccine coverage requirements, the uncertainty has forced states and health plans to independently maintain coverage policies, creating implementation complexity. The article explores how public health stakeholders are adapting to fill federal policy gaps through alternative recommendation pathways and trust-building efforts.

CMS is overhauling kidney care through transplant system modernization, new organ procurement standards, and the mandatory IOTA Model launched in mid-2025, while simultaneously sunsetting underperforming value-based care models like ESRD Treatment Choices. The piece examines how federal payment reforms, emerging xenotransplant technology, and refined Kidney Care Choices models are reshaping the dialysis and transplant ecosystem. While primarily Medicare-focused, these structural changes affect Medicaid managed care plans covering dual-eligible populations and states with integrated care models for members with end-stage renal disease.

The 2026 CMS Quality Conference outlined major policy directions affecting both Medicare and Medicaid managed care, emphasizing prevention-focused models, technology-enabled whole-person care, real-time quality measurement, and AI integration. CMS leadership signaled that quality strategies will increasingly prioritize upstream preventive interventions and align payment incentives with clinical outcomes, requiring health plans to demonstrate how their programs contribute to prevention and reduce downstream utilization. These emerging federal priorities will shape how Medicaid MCOs structure their quality improvement programs, demonstrate value, and respond to evolving state contract requirements.

Medicaid programs are increasingly moving away from bundled payment methodologies for cell and gene therapies in order to separately identify these drugs and collect manufacturer rebates under the Medicaid Drug Rebate Program. This shift provides more predictable reimbursement for providers but increases rebate exposure for manufacturers. The piece also explores the expansion of CAR-T administration into community outpatient settings and implications for access and reimbursement across payer types.

Avalere examines how state Medicaid programs are responding to budget pressure from the One Big Beautiful Bill Act, new provider tax restrictions, and rising utilization. States are adjusting managed care rates, benefits packages, and procurement timelines to navigate tighter fiscal conditions while managing administrative constraints. The analysis outlines decision-making factors that will shape state actions affecting MCO contracts and payment structures in the current budget cycle.

Gene therapies for rare diseases create structural tension between one-time treatments with multi-decade outcomes and payer systems built on annual budgets and short-term evidence cycles. With 26 FDA-approved gene therapies now in use and more coming, the piece argues healthcare delivery infrastructure and financing models—not just clinical science—will determine patient access and long-term sustainability. For Medicaid MCOs, this raises questions about payment structures, coverage decisions, and evidence generation obligations for high-cost, one-time interventions.

The U.S. Pharmacopeia's 2026 Drug Classification update revises how drugs are grouped for non-Part D health plan formularies, including Medicaid managed care plans. While primarily focused on Medicare Part D guidance, these classifications influence how all health plans structure formularies and could affect drug eligibility for upcoming Medicare international reference pricing demonstrations. The annual update cycle for non-Part D classifications offers Medicaid plans more frequent opportunities to engage on drug categorization than the three-year Medicare cycle.

The 340B drug discount program reached $81.4 billion in 2024, with disproportionate share hospitals accounting for 78% of purchases. Many DSH hospitals also participate in Medicaid managed care, and pending federal reforms—including the 340B Rebate Model pilot and congressional bills—could reshape how these entities finance care for Medicaid beneficiaries. The program now exceeds Medicaid drug spending, making potential policy changes significant for state programs and MCOs contracting with 340B-eligible providers.

The reconstituted Advisory Committee on Immunization Practices made changes to pediatric immunization schedules in December 2025 and signaled potential 2026 policy shifts affecting vaccines for HPV, RSV, influenza, and pregnancy-related immunizations. Because ACIP recommendations trigger mandatory Medicaid coverage without cost-sharing when published in official immunization schedules, these deliberations—and the committee's altered composition and process—carry direct implications for MCO benefit design, preventive care obligations, and pediatric and maternal health programs. The exclusion of traditional medical society liaisons from work groups may affect the clinical grounding of future recommendations that Medicaid plans must operationalize.

Major changes to the Advisory Committee on Immunization Practices—including replacement of all members and elimination of expert working groups—may affect Medicaid coverage requirements, since ACIP recommendations trigger mandatory coverage under federal law and determine which vaccines qualify for the Vaccines for Children program. The white paper examines how these structural changes could disrupt the evidence-based processes that underpin Medicaid immunization benefits and patient access protections.